The Nasdaq Stock Market opens in less than five hours and Moderna’s premarket value is already 4.29% down.

Last session, the Nasdaq Stock Market finished with Moderna falling 8.98% to $125.88. The Nasdaq Stock Market rose 0.51% to $12,807.90, after two successive sessions in a row of losses, on what was a somewhat positive trend trading session.

Moderna’s last close was $138.30, 41.80% under its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company’s growth estimates for the present quarter is a negative 2.7% and positive 660% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $125.88 at 05:18 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s value is above its 50-day moving average of $116.47 and way higher than its 200-day moving average of $80.87.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company’s coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Moderna Inc. and BioNTech SE both fell more than 9% in heavy volume as the vaccine makers saw their worst day in the stock market since late November.", "The leading U.S. Covid-19 vaccine makers sank on Tuesday as Moderna slumped 11% and BioNTech fell almost 10%. "


Please enter your comment!
Please enter your name here